Zymeworks Inc
For the period ended Dec 31, 2024. Filed Mar 5, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 5, 2025
ZYME$31.46+2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as at December 31, 202 and
Consolidated Balance Sheets
(Expressed in thousands of U.S. dollars except share data)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $66,103 | $157,557 |
| Short-term marketable securities (note 5) | 159,673 | 216,770 |
| Accounts receivable | 55,815 | 19,477 |
| Prepaid expenses and other current assets | 18,860 | 19,122 |
| Total current assets | 300,451 | 412,926 |
| Long-term marketable securities (note 5) | 98,428 | 81,930 |
| Long-term prepaids and other assets | 8,919 | 7,566 |
| Deferred tax asset (note 13) | 4,385 | 3,615 |
| Property and equipment, net (note 7) | 17,650 | 19,847 |
| Operating lease right-of-use assets (note 14) | 16,666 | 17,696 |
| Intangible assets, net (note 8) | 4,576 | 7,656 |
| Acquired in-process research and development assets (“IPR&D”) (note 6) | — | 17,628 |
| Goodwill (note 6) | 12,016 | 12,016 |
| Total assets | $463,091 | $580,880 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities (note 9) | $59,838 | $45,992 |
| Income tax payable (note 13) | 128 | 1,811 |
| Current portion of operating lease liability (note 14) | 2,740 | 4,261 |
| Deferred revenue and other consideration (note 11) | 25,588 | 3,699 |
| Total current liabilities | 88,294 | 55,763 |
| Long-term portion of operating lease liability (note 14) | 15,738 | 22,369 |
| Deferred revenue (note 11) | 14,607 | 32,941 |
| Other long-term liabilities (note 9) | 923 | 1,701 |
| Deferred tax liability (note 13) | 4,761 | 3,300 |
| Total liabilities | 124,323 | 116,074 |
| Stockholders’ equity: | ||
| Common shares, $0.00001 par value; 900,000,000 authorized shares of common stock at December 31, 2024 and December 31, 2023 (68,964,319 and 70,115,997 shares issued and outstanding at December 31, 2024 and 2023, respectively (note 10b). | 1,015,618 | 997,227 |
| Preferred shares, $0.00001 par value; 100,000,000 authorized shares of preferred stock, out of which, one share of preferred stock is a share of Special Voting Preferred Stock and outstanding as of December 31, 2024 and December 31, 2023 (note 10b). | — | — |
| Exchangeable shares, no par value, 570,637 issued and outstanding shares at December 31, 2024 (December 31, 2023: 651,219) (note 10b). | 8,188 | 9,345 |
| Additional paid-in capital | 152,249 | 142,274 |
| Accumulated other comprehensive loss | (6,952) | (6,603) |
| Accumulated deficit | (830,335) | (677,437) |
| Total stockholders’ equity | 338,768 | 464,806 |
| Total liabilities and stockholders’ equity | $463,091 | $580,880 |
| Research collaboration and licensing agreements (note 11) | ||
| Commitments and contingencies (note 15) | ||
| Subsequent event (note 17) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.